1. |
ADVANCE NEXT: Phase 3 study of intravenous efgartigimod in primary immune thrombocytopenia (口頭発表,一般) 2025/06/23
|
2. |
Effect of Intravenous Efgartigimod on Immature Platelet Fraction inPrimary Immune Thrombocytopenia (口頭発表,一般) 2025/06/23
|
3. |
LUNA3 open-label period: First efficacy/safety with rilzabrutinib in previously treated ITP adults (口頭発表,一般) 2025/06/23
|
4. |
Platelet responses per IWG criteria for LUNA3 rilzabrutinib vs placebo in primary ITP patients (口頭発表,一般) 2025/06/22
|
5. |
Early initiation of TPO-RA reduces total corticosteroid dose in adult ITP: Japanese database analysis (ポスター,一般) 2025/06/21
|
6. |
Health-Related Quality of Life and Joint Health with Giroctocogene Fitelparvovec Gene Therapy (口頭発表,一般) 2025/06/20
|
7. |
エクリズマブから切替えたaHUS患者のラブリズマブ製造販売後調査の解析 (ポスター,一般) 2025/06/20
|
8. |
PHASE 3 LUNA3 STUDY: FIRST EFFICACY/SAFETY REPORT OF LONG-TERM EXTENSION PERIOD WITH RILZABRUTINIB IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) (口頭発表,一般) 2025/06/13
|
9. |
Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia (口頭発表,一般) 2025/06/12
|
10. |
Efgartigimod IV for the Treatment of Primary Immune Thrombocytopenia: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study With Open-Label Period (ADVANCE NEXT) (口頭発表,一般) 2025/06/12
|
11. |
CLINICAL FACTORS ASSOCIATED WITH RESPONSE TO RILZABRUTINIB, A BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) TREATED IN THE PHASE 3 LUNA3 STUDY (口頭発表,一般) 2025/06/11
|
12. |
Ravulizumab in atypical haemolytic uraemic syndrome: analysis of quality of life outcomes in adult and pediatric phase 3 trials (ポスター,一般) 2025/06/04
|
13. |
Efficacy and safety of ora bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo controlled, parallel group, multi-center study (LUNA3) (口頭発表,一般) 2025/03/29
|
14. |
Bleed protection after giroctocogene fitelparvovec infusion in adults with moderately severe to severe hemophilia A in the phase 3 AFFINE trial. (ポスター,一般) 2025/02/04
|
15. |
Clinical management of factor VIII elevations above normal ranges post giroctocogene fitelparvovec in Phase 3 AFFINE study (口頭発表,一般) 2025/02/04
|
16. |
Efficacy and safety of oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib in adults with previously treated immune thrombocytopenia (ITP): a phase 3, placebo-controlled, parallel-group, multicenter study (LUNA3) (口頭発表,一般) 2024/12/08
|
17. |
Improved health-related quality of life (HR-QOL) with oral bruton tyrosine kinase inhibitor (BTKi) rilzabrutinib vs placebo in adults with previoulsy treated immune thrombocytopenia (ITP): phase 3 LUNA3 multicenter study (ポスター,一般) 2024/12/08
|
18. |
Intravenous efgartigimod for the treatment of primary immune thrombocytopenia in adults: a planned, phase 3, randomised, double-blindded, placebo-controlled, parallel-arm study with open label period (ADVANCE NEXT) (口頭発表,一般) 2024/12/08
|
19. |
Safety and efficacy of efgartigmod in primary immune thrombocytopenia: ADVANCE IV+ 2 year analysis (口頭発表,一般) 2024/11/06
|
20. |
Ravulizumab in atypical hemolytic uremic syndrome: final analysis of efficacy and safety outcomes in two phase 3 trials. (口頭発表,一般) 2024/10/23
|
21. |
Baseline characteristics of Asian patients with persistent and chronic ITP enrolled in LUNA 3 trial (口頭発表,一般) 2024/10/12
|
22. |
Safety and efficacy of efgartigimod in primary immune thrombocytopenia: ADVANCE+ interim 2 year analysis (口頭発表,一般) 2024/10/12
|
23. |
BASIC CHARACTERISTICS OF ADULT PATIENTS WITH PREVIOUSLY TREATED IMMUNE THROMBOCYTOPENIA ENROLLED IN LUNA 3 PHASE 3 PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR (ポスター,一般) 2024/10/11
|
24. |
Post hoc analysis of ADAMTS13 activity and inhibitors in a phase 2/3 sutdy in Japanese patients with iTTP treated with caplacizumab (ポスター,一般) 2024/06/22
|
25. |
Time to platelet count response afetr IV efgartigimod in primary ITP (口頭発表,一般) 2024/06/15
|
26. |
Basic characteristics of adult patients with previously treated immune thrombocytopenia enrolled in LUNA3 phase 3 placebo-controlled study of rilzabrutinib, an oral bruton tyrosine kinase inhibitor (抄録提出,一般) 2024/06/13
|
27. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): 2 year follow up from the CARDINAL study (口頭発表,一般) 2023/06/09
|
28. |
Long term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia: interim results of the ADVANCE+ study (口頭発表,一般) 2023/06/08
|
29. |
Intravenous efgartigimod in adults with primary immune thrombocytopenia: results from the ADVANCE IV trial. (口頭発表,一般) 2023/04/25
|
30. |
SARS-Cov-2ワクチン接種後に発症した後天性血栓性血小板減少性紫斑病 (口頭発表,一般) 2023/03/11
|
31. |
後天性血友病A患者の出血リスクが高い経皮腎瘻造設術に対するエミシズマブとrFVIIaによる周術期管理 (口頭発表,一般) 2023/03/11
|
32. |
Efficacy and safety of intravenous Efgartigimod in adults with primary immune thrombocytopenia: results of ADVANCE IV, a Phase 3, multicentr, double-blinded, placebo-controlled, randomized clinical trial (口頭発表,一般) 2022/12/11
|
33. |
HELLP症候群との鑑別を要する妊娠関連TMA (口頭発表) 2022/10/29
|
34. |
Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome: Analysis of Two Phase 3 Studies (ポスター,一般) 2022/10/17
|
35. |
後天性血栓性血小板減少性紫斑病(TTP)診断と新規治療:抗VWF抗体カプラシズマブ (口頭発表) 2022/10/16
|
36. |
Efficacy and safety of caplacizumab for thrombotic thrombocytopenic purpura: Japanese Phase 2/3 study (口頭発表,一般) 2022/10/15
|
37. |
Phamacokinetic and pharmacodynamic simulations guide selection of the dose for administration of efgartigimod PH20 subcutaneously in a Phase 3 clinical trial in patients with primary immune thrombocytopenia (口頭発表,一般) 2022/09/26
|
38. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): a 2 year follow up from the CARDINAL study (口頭発表,一般) 2022/06/10
|
39. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin diseasse (CAD): 2 year follow up from the CADRINAL study (口頭発表,一般) 2022/06/10
|
40. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study (ポスター,一般) 2022/06/09
|
41. |
Inhibition of complement C1s with sutimlimab in patients with cold aggulutinin disease , results following 9 week wash out period in phase 3 cardinal study. (ポスター,一般) 2022/06/09
|
42. |
Sutimlimab, a complement C1s inhibitor, provides sustained improvements in patient-reported outcomes in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study (ポスター,一般) 2022/06/09
|
43. |
Eculizumab for adult patients with atypical haemolytic uremic syndrome: full dataset analysis of post-marketing surveillance in Japan (口頭発表,一般) 2022/05/20
|
44. |
La modélisation pharmacocinétique-pharmacodynamique supporte la sélection de la dose d'efgartigimod à administrer par voie sous-cutanée dans un essai clinique de phase 3 chez des patients atteints de purpura thrombopénique immunologique (ポスター,一般) 2021/12/16
|
45. |
Two year efficacy and safety of ravulizumab in adults and children with atypical HUS: analysis of two phase 3 studies. (口頭発表,一般) 2021/12/06
|
46. |
Phamakokinetic and pharmakodynamic simulations guide selection of the dose for administration of Efgartigimod PH20 subctutaneously in a phase 3 clinical trial in patients with primary immune thrombocytopenia (口頭発表,一般) 2021/12/05
|
5件表示
|
全件表示(46件)
|